Method for Cancer Therapy Based on Co-Administration of a Parvovirus and a Cytokine
US-2016367609-A1 · Dec 22, 2016 · US
Use of parvovirus for eliminating cancer stem cells (CSCs)
US9700588B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9700588-B2 |
| Application number | US-201113807736-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 29, 2011 |
| Priority date | Jul 7, 2010 |
| Publication date | Jul 11, 2017 |
| Grant date | Jul 11, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Described is the use of a parvovirus, preferably H-1PV, for the therapeutical elimination of cancer stem cells (CSCs), preferably neuroblastoma stem cells and glioblastoma stem cells.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of combating potentially relapsing glioblastoma stem cells in a subject having metastatic glioblastoma, comprising administering to said subject a composition comprising parvovirus H-1 (H-1PV) effective for therapeutically destroying said potentially relapsing glioblastoma stem cells. 2. The method of claim 1 , wherein said composition is administered by intravenous (i.v.), intratumoral, intracranial or intracerebral administration. 3. The method of claim 1 , wherein said composition further comprises a pharmaceutically acceptable carrier. 4. A method of combating glioblastoma stem cells in a subject suffering from a glioblastoma relapse, comprising administering to said subject a composition comprising parvovirus H-1 (H-1PV) effective for therapeutically destroying said glioblastoma stem cells. 5. The method of claim 4 , wherein said composition is administered by intravenous (i.v.), intratumoral, intracranial or intracerebral administration. 6. The method of claim 4 , wherein the glioblastoma stem cells are potentially relapsing glioblastoma stem cells. 7. The method of claim 4 , wherein said composition further comprises a pharmaceutically acceptable carrier.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Antineoplastic agents · CPC title
Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent · CPC title
- A61K35/768Primary
Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766 · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9700588B2 cover?
- Described is the use of a parvovirus, preferably H-1PV, for the therapeutical elimination of cancer stem cells (CSCs), preferably neuroblastoma stem cells and glioblastoma stem cells.
- Who is the assignee on this patent?
- Rommelaere Jean, Lacroix Jeannine, Schlehofer Joerg, and 8 more
- What technology area does this patent fall under?
- Primary CPC classification A61K35/768. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jul 11 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).